Smolen JS - Search Results

1

Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.

Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, Samsonov MY, Fleischmann RM; CREDO2 Group. Smolen JS, et al. N Engl J Med. 2022 Aug 25;387(8):715-726. doi: 10.1056/NEJMoa2201302. N Engl J Med. 2022. PMID: 36001712 Clinical Trial.

2

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, et al. Elliott MJ, et al. Among authors: smolen js. Lancet. 1994 Oct 22;344(8930):1105-10. doi: 10.1016/s0140-6736(94)90628-9. Lancet. 1994. PMID: 7934491 Clinical Trial.

3

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R. Smolen JS, et al. Lancet. 1999 Jan 23;353(9149):259-66. doi: 10.1016/s0140-6736(98)09403-3. Lancet. 1999. PMID: 9929017 Clinical Trial.

4

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Maini R, et al. Lancet. 1999 Dec 4;354(9194):1932-9. doi: 10.1016/s0140-6736(99)05246-0. Lancet. 1999. PMID: 10622295 Clinical Trial.

5

Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis.

Smolen JS. Smolen JS. Scand J Rheumatol Suppl. 1999;112:15-21. doi: 10.1080/030097499750042245-1. Scand J Rheumatol Suppl. 1999. PMID: 10668523 Clinical Trial.

6

Efficacy and safety of leflunomide in active rheumatoid arthritis.

Smolen JS, Emery P. Smolen JS, et al. Rheumatology (Oxford). 2000 Jun;39 Suppl 1:48-56. doi: 10.1093/oxfordjournals.rheumatology.a031495. Rheumatology (Oxford). 2000. PMID: 11001380

7

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Lipsky PE, et al. Among authors: smolen js. N Engl J Med. 2000 Nov 30;343(22):1594-602. doi: 10.1056/NEJM200011303432202. N Engl J Med. 2000. PMID: 11096166 Free article. Clinical Trial.

8

Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: clinical evaluation and cost analysis.

Aletaha D, Smolen JS. Aletaha D, et al. Among authors: smolen js. Arthritis Rheum. 2002 Apr 15;47(2):181-8. doi: 10.1002/art.10266. Arthritis Rheum. 2002. PMID: 11954012 Free article.

9

Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study.

Aletaha D, Smolen JS. Aletaha D, et al. Among authors: smolen js. J Rheumatol. 2002 Aug;29(8):1631-8. J Rheumatol. 2002. PMID: 12180721

10

The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.

Aletaha D, Smolen JS. Aletaha D, et al. Among authors: smolen js. Rheumatology (Oxford). 2002 Dec;41(12):1367-74. doi: 10.1093/rheumatology/41.12.1367. Rheumatology (Oxford). 2002. PMID: 12468815

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

821 results

Search Page